RCT: In children with peanut allergy, initiation of peanut oral immunotherapy before age 4 years induced desensitization in 71% of patients and remission in 21%.
24 Jan, 2022 | 08:18h | UTCEfficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link to abstract – $ for full-text)
News Release: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases
Commentary: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay